- ISIN
- AGP8696W1045
- CUSIP
- P8696W104
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 3, 2003
Highlights
- Total Revenue (TTM)
- $1.94B
- Gross Profit (TTM)
- $1.07B
- EBITDA (TTM)
- -$311.05M
- Year Range
- $6.47 - $6.47
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SVA Performance Chart
Sinovac Biotech Ltd (SVA) is up 0.0% since the beginning of the year. At $6 per share, SVA is currently trading at its 52-week high.
Loading charts...
Returns By Period
Sinovac Biotech Ltd (SVA) has returned 0.00% so far this year and 0.00% over the past 12 months.
Sinovac Biotech Ltd
- 1D
- 0.00%
- 1M
- 0.00%
- YTD
- 0.00%
- 6M
- 0.00%
- 1Y
- 0.00%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
SVA Monthly Returns History
Based on dividend-adjusted daily data since Mar 11, 2025, SVA's average daily return is 0.00%, while the average monthly return is 0.00%.
Historically, 0% of months were positive and 100% were negative. The best month was Mar 2025 with a return of 0.0%, while the worst month was Mar 2025 at 0.0%. The longest winning streak lasted 0 consecutive months, and the longest losing streak was 0 months.
On a daily basis, SVA closed higher 0% of trading days. The best single day was Mar 11, 2025 with a return of 0.0%, while the worst single day was Mar 11, 2025 at 0.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||||
| 2025 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Benchmark Metrics
0- Alpha
- 0.00%
- Beta
- 0.00
- Upside Capture
- 0.00%
- Downside Capture
- -0.00%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Sinovac Biotech Ltd (SVA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SVA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | — | 1.37 | — |
| Calmar ratioReturn relative to maximum drawdown | — | 2.78 | — |
| Martin ratioReturn relative to average drawdown | — | 12.44 | — |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Sinovac Biotech Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The portfolio has not yet recovered.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|
Drawdown Indicators
| SVA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | 0.00% | -56.78% | +56.78% |
Max Drawdown (1Y)Largest decline over 1 year | 0.00% | -9.10% | +9.10% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | 0.00% | -1.80% | +1.80% |
Average DrawdownAverage peak-to-trough decline | 0.00% | -10.71% | +10.71% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 0.00% | 2.03% | -2.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Sinovac Biotech Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Sinovac Biotech Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SVA
Add Sinovac Biotech Ltd to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SVA